The present study showed that current GLP-1 RA use was not associated with a decreased risk of any fracture, as compared to the use of other anti-hyperglycemic drugs, and current GLP-1 RA use was not associated with a reduced risk of other fracture types. This evidence concerns the gene GLP1R and rheumatoid arthritis.